Biotech News

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer

NGM Biopharmaceuticals (NGM)NGM Biopharmaceuticals2025-02-04 12:00 ESTCompany update

Dr. Yeh will oversee the continued clinical development of NGM Bio’s key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc.

Related news

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

GERNGeron2026-07-13 12:00 EST

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

View all latest news

NGM Biopharmaceuticals

NGM Biopharmaceuticals is a biotech company focused on metabolic, liver, and oncology programs. Its business has been shaped by a broad platform approach and ongoing portfolio decisions.

Recent company news

NGMNGM Biopharmaceuticals2025-02-24 08:00 EST

NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients

NGMNGM Biopharmaceuticals2025-02-04 12:00 EST

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer

NGMNGM Biopharmaceuticals2024-12-19 12:01 EST

NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate

NGMNGM Biopharmaceuticals2024-07-17 11:01 EST

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

NGMNGM Biopharmaceuticals2024-04-05 13:20 EST

NGM Bio Announces Closing of Tender Offer

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States